<DOC>
	<DOCNO>NCT00092547</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , immune response investigational vaccine preadolescent adolescent boys girls prevention Human Papilloma Virus ( HPV ) .</brief_summary>
	<brief_title>A Study Gardasil ( V501 ) Preadolescents Adolescents ( V501-018 )</brief_title>
	<detailed_description>The original base protocol ( V501-018 ) ( NCT00092547 ) extend amendment V501-018-05 -06 provide 37 month follow-up . Additionally , subject Placebo Group base study give 3 dos open-label GARDASILâ„¢ ( V501 ) Months 30 , 32 , 36 . The study extend amendment V501-018-10 ( NCT00092547 ) , title `` A Long Term Immunogenicity , Safety , Effectiveness Study GARDASIL ( Human Papillomavirus [ Types 6 , 11 , 16 , 18 ] Recombinant Vaccine ) Among Adolescents Who Received GARDASIL 9-18 Years Age '' allow follow-up period Month 126 .</detailed_description>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adolescent preadolescents prior sexual history Subjects compromise immune system history severe allergic reaction</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>